Sai Parenterals Ltd (SAIPARENT) — shareholding pattern, promoter holding, financials and share price
About Sai Parenterals Ltd (SAIPARENT)
Sai Parenterals Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SAIPARENT and on the BSE under scrip code 544742. Its ISIN is INE0H9F01037.
Incorporated in 2001, Sai Parenteral's Ltd. is a diversified pharmaceutical formulations company with expertise in research, development, and manufacturing. [1]
Listed peers in Pharmaceuticals: Hikal Ltd, Solara Active Pharma Sciences Ltd, Kwality Pharmaceuticals Ltd, Indoco Remedies Ltd, Beta Drugs Ltd, Venus Remedies Ltd.
Valuation & Returns
10 Jul 2026At ₹587.25 a share on 10 Jul 2026, Sai Parenterals Ltd (SAIPARENT) was valued at a price-to-earnings ratio of -61.84x and a price-to-book of 2.52x on a book value of ₹97.22 per share. Solomo computes return on equity of 3.03% and return on capital employed of 3.56% from filed results.
- P/E
- -61.84x
- P/B
- 2.52x
- EPS (TTM)
- ₹-3.96
- Book value / share
- ₹97.22
- ROE
- 3.03%
- ROCE
- 3.56%
- ROA
- -2.06%
- Debt / equity
- 0.57x
- Dividend yield
- 0.25%
- EBITDA margin
- 8.71%
- 52-week range
- ₹145.95 – ₹355
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Sai Parenterals Ltd (SAIPARENT) reported revenue of ₹381 crore, net profit of ₹14 crore and earnings per share of ₹3.23. That compares with revenue of ₹163 crore and net profit of ₹14 crore in Mar 2025. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹198 crore and net profit ₹13 crore (consolidated).
| Metric | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| Revenue (₹ cr) | 97 | 154 | 163 | 381 |
| Net profit (₹ cr) | 4 | 8 | 14 | 14 |
| EPS (₹) | 6.13 | 6.36 | 5.43 | 3.23 |
| Measure | 1Y |
|---|---|
| Sales growth | 6.08% |
| Profit growth | 71.62% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 51.16% of Sai Parenterals Ltd (SAIPARENT) (unchanged from the previous quarter), foreign institutional investors (FII) hold 4.03% and domestic institutional investors (DII) hold 8.53%. Market capitalisation was ₹2,594 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2026.
Largest disclosed public shareholders in Jun 2026: BHASKARA RAO BOLLINENI 4.56%, SAMARSH CAPITAL-SAMARSH CAPITAL-FUND I 3.45%, KOTAK MAHINDRA LIFE INSURANCE COMPANY LTD. 2.35%, AIG DIRECT LLC 2.12%, AGILIS PARTNERS LLP 2.06%, KOTAK LIFE SCIENCES FUND I 1.73%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 51.16% | - | 4.03% | 8.53% | 48.84% |
| Mar 2026 | 51.16% | - | 5.73% | 12.86% | 48.84% |